Lamivudine/raltegravir

Lamivudine/raltegravir, sold under the brand name Dutrebis, is a fixed-dose combination antiretroviral medication used in the treatment of HIV/AIDS.[1] It contains lamivudine and raltegravir. It is taken by mouth.[1] Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes.[1] It was approved for medical use in the United States in 2015.[1][2]

Lamivudine/raltegravir
Combination of
LamivudineReverse-transcriptase inhibitor
RaltegravirIntegrase inhibitor
Clinical data
Trade namesDutrebis
Routes of
administration
Oral
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Lamivudine/raltegravir is not available in the United States.[3]

References

  1. "Dutrebis (lamivudine and raltegravir)" (PDF). U.S. Food and Drug Administration (FDA). Retrieved 10 December 2017.
  2. "Dutrebis (lamivudine and raltegravir) tablet". U.S. Food and Drug Administration (FDA). 11 April 2016. Retrieved 24 January 2020.
  3. "Dutrebis (lamivudine and raltegravir) FDA Approval History". Drugs.com. 6 February 2015. Retrieved 24 January 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.